NASDAQ · Biotechnology

Veracyte, Inc. (VCYT) Stock

$43.60 +1.02% NASDAQ: VCYT Healthcare

Valuation

MetricValue
Price$43.60
Market Cap$3.48B
P/E Ratio31.81
P/B Ratio2.63
P/S Ratio6.51
EPS (TTM)$0.82
52-Week High$60.91
52-Week Low$29.45
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE8.64%
ROA7.70%
ROCE6.72%
Gross Margin14.31%
Operating Margin14.31%
Net Margin20.37%
Debt/Equity0.03
Current Ratio8.13

Annual Financials (USD)

Metric20212022202320242025
Revenue$220.0M$297.0M$361.0M$446.0M$517.0M
Operating Profit$-82.0M$-41.0M$-86.0M$16.0M$74.0M
Net Profit$-76.0M$-37.0M$-74.0M$24.0M$66.0M
EPS$-1.11$-0.51$-1.02$0.31$0.82
Op Margin-37.3%-13.8%-23.8%3.6%14.3%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$1.2B$1.2B$1.1B$1.3B$1.4B
Total Liabilities$91.0M$81.0M$71.0M$124.0M$96.0M
Cash$173.0M$154.0M$216.0M$239.0M$363.0M
Borrowings$19.0M$15.0M$13.0M$51.0M$40.0M

Latest News

What to Know About This $197,000 Veracyte Insider Sale After a 120% Stock Rally Motley Fool · Jun 27, 2026 This Top Stock Has Surged. CEO Explains Key To Veracyte's Success. Investor's Business Daily · Jun 18, 2026 Dow Jones Futures: Techs Rebound, SpaceX Rises Despite Trump's Iran Threat; Warsh's Fed Debut Due Investor's Business Daily · Jun 17, 2026 Here's How Much a $1000 Investment in Veracyte Made 10 Years Ago Would Be Worth Today Zacks · Jun 10, 2026 Veracyte Insider Sold Shares Worth $6,919,585, According to a Recent SEC Filing MT Newswires · Jun 5, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-32.0M$8.0M$44.0M$75.0M$136.0M
Investing Cash Flow$-745.0M$-38.0M$5.0M$-68.0M$-19.0M
Financing Cash Flow$2.0M$5.0M$3.0M$-15.0M$-18.0M
Net Cash Flow$-176.0M$-19.0M$62.0M$23.0M$124.0M
Free Cash Flow$-37.0M$-1.0M$34.0M$64.0M$127.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.10
EV / EBITDA26.17
FCF Yield4.53%
Quick Ratio8.80
Interest Coverage0.00
Return 1Y58.16%
Return 3Y80.64%
Return 5Y55.55%

Ownership

Insiders Held0.54%
Institutions Held112.66%
Institutions Float Held113.27%
Institutional HolderSharesReport Date
Blackrock Inc.13,172,6182026-03-31
FMR, LLC7,763,8492026-03-31
Artisan Partners Limited Partnership5,496,3702026-03-31
State Street Corporation5,043,5902026-03-31
Vanguard Portfolio Management LLC4,444,7302026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AAPLApple Inc. $340.42 +1.11% 38.93 $5.00T 0.32%
MSFTMicrosoft Corporation $522.61 -1.35% 28.68 $3.88T 0.76%
GOOGLAlphabet Inc. $348.29 -0.63% 16.94 $4.22T 0.26%
AMZNAmazon.com, Inc. $254.06 -2.25% 19.82 $2.73T 0.00%
METAMeta Platforms, Inc. $720.89 -0.06% 27.93 $1.84T 0.28%

About Veracyte, Inc.

Veracyte, Inc. (VCYT) stock trades at $43.60 with a market capitalization of $3.48B. The stock is valued at a price-to-earnings (P/E) ratio of 31.81, price-to-book of 2.63, price-to-sales of 6.51. Over the past 52 weeks the stock has ranged between $29.45 and $60.91, and currently trades 28.4% below its 52-week high.

On profitability, Veracyte, Inc. generates a return on equity (ROE) of 8.64%, return on capital employed of 6.72%, an operating margin of 14.31%, a net profit margin of 20.37%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1169.93 -1.58% JNJ Johnson & Johnson $256.48 -0.76% ABBV AbbVie Inc. $272.42 +0.39% MRK Merck & Company, Inc. Common Stock (new) $142.40 -0.28% UNH UnitedHealth Group Incorporated Common Stock (DE) $370.95 -1.34% NVS Novartis AG $143.11 -0.12% AZN AstraZeneca PLC $158.78 -0.84% TMO Thermo Fisher Scientific Inc $651.98 -1.52% AMGN Amgen Inc. $407.44 -1.37% GILD Gilead Sciences, Inc. $147.10 +0.17% ABT Abbott Laboratories $98.49 -0.24% NVO Novo Nordisk A/S $38.18 -0.21%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides